Futura Medical Share Discussion Threads

[mdi] 17/7/2023 08:33

No reference to the patent or if it is all subject to a patent being granted?

[roberth176] 17/7/2023 08:32

Someone is for sure otherwise it would have been flying moreTherefore new short in play as odey will keep selling now and price willDropAnd drop

[petroc] 17/7/2023 08:32

LiarBOoth's assessment of yesterdays brilliantly prescient article in the Sunday Times:

'Yet another poorly researched article by a ‘tipster’;.

LiarBOoth couldn't spot good advice if it punched him in the face! What an utter loser! No wonder he's spent 6 years of his life whinging and whining about FUM, when everyone else has been making money!

[johnjames876] 17/7/2023 08:28

Looks like odey are dumping

[petroc] 17/7/2023 08:22

Glavey13 Jul '23 - 13:45 - 19307 of 19343
Well, would you believe it Pet, the share price is falling during 'risk on' days. What do you make of that?

thebutler13 Jul '23 - 12:09 - 19302 of 19343
Next leg down!

Bwahahahaha! Bwahahaha!

[oxford43] 17/7/2023 08:04

Haleon market cap £29billion!

[j777j] 17/7/2023 07:54

Incredible news to have Glaxo spin off Haleon take up the product


Despite the massive efforts to discredit the co it has pulled off the jackpot



Well done to all those that ignored the noise

[ajmace] 17/7/2023 07:47

Could be set for the 70s today.Haleon are part of the old GSK so hardly a small time player.They obviously believe in the product.Well done to all long term holders

[heialex1] 17/7/2023 07:39

Huge validation!!

[bloomberg2] 17/7/2023 07:31

It's always been a firm favourite of mine this one

[penciles2] 17/7/2023 07:25

It will run hard today on that news

[broomrigg] 17/7/2023 07:15

RNSNICE APPLES;-)

[halfpenny] 17/7/2023 03:58

FUM maybe FUN at these levels

[broomrigg] 16/7/2023 20:55

The thick loser must LOVE seeing FUM tipped in The Times lollllllllllHILARIOUS

[broomrigg] 16/7/2023 15:47

Thanks for posting that link to the BUY recommendation in today's Times BEANOL. NICE ONE. Here is the article in full peeps ........

Futura is looking for rapid growth

Lucy Tobin
Sunday July 16 2023, 12.01am, The Sunday Times

Futura Medical is an Aim-listed pharmaceuticals tiddler, with only 14 staff and directors, which sells a single, brand-new gel. It works out of a small Surrey University science park, and its share price has surged by 84 per cent since last year. So it’s not the obvious contender for a share tip.

However, Futura has made a new product that works, and it is only just starting to shout about it. The company’s Eroxon gel is the first erectile dysfunction product approved to go on sale without a prescription. It is already available at Boots and online via the likes of Amazon, and it is the first new ED treatment for two decades. Clinical trials showed Eroxon successfully pumped up 65 per cent of users. Given the scale of the stigma-ridden, $3 billion (£2.3 billion) global market for men suffering a lack of erections — it is forecast to surpass $6 billion by 2032 — Futura looks appealing.

Rival treatments, such as Viagra and Cialis, both need a prescription and take longer to work: the Eroxon gel acts in ten minutes; it’s half an hour with rivals.


Futura has also minimised risk by outsourcing all it can: it does the science, but then, said chief executive James Barder, looks for “commercial partners to do the rest” — the marketing and distribution. “We’ve done so in the UK, Europe, and seven countries in the Middle East. Saudi [Arabia’s] approval is expected in September — that’s the biggest erectile dysfunction market in the Middle East — and we are working on a US partner .”

America has the world’s highest number of ED sufferers by far, and Barder said Futura had “interest from a number of parties”. Signing a commercial deal there would be likely to trigger a share price surge.


“The announcement of that US partner will be crucial as it’s very early days for Eroxon,” said Seb Jantet, an analyst at house broker Liberum. “But there are early signs of success.”

In the UK, where Futura’s product first hit Boots’s shelves exclusively in April, almost £2 million worth of Eroxon was sold in the first eight weeks, the firm told capital market day attendees last month. Its launch partner said it had been one of its most successful over-the-counter launches.

Futura is anticipating sales of £3 million this year — stocking orders from the small markets of the UK and Belgium. “These don’t really show the scale of what the product could do,” Jantet added. But Futura has more than £4 million in cash and a strong balance sheet. There are no guarantees of a happy ending, but it’s a worthy punt. Buy.

[halfpenny] 16/7/2023 14:10

FUM maybe FUN at these levels